June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually. The shot ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

The FDA approved Pfizer's maternal vaccine to protect newborns from RSV. Courtesy Pfizer Still, the vaccine, given from 32 to 36 weeks of gestational age, does not provide long-term protection.

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making.

The EU had previously approved two vaccines for protecting ... "This approval of the first mRNA vaccine against RSV clearly shows the importance of innovation when it comes to protecting the ...

The Food and Drug Administration on Wednesday licensed the first-ever vaccine for respiratory syncytial virus, or RSV, completing an elusive quest that has been decades in the making. The product ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC ...